Much of this decline can be attributed to the company’s weaker-than-expected performance ... citing issues with a third-party supplier. Given the substantial fall in Regeneron’s stock price ...

Additionally, prolonged regulatory issues could provide competitors ... which could significantly impact Regeneron’s stock performance and long-term prospects. For the most comprehensive analysi ...

Additionally, prolonged regulatory issues could provide competitors with opportunities ... which could significantly impact Regeneron’s stock performance and long-term prospects. For the most ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab) significantly outperformed Xolair (omalizumab) in treating adults with severe ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Annual Shareholders Meeting was a governance-heavy affair, with proposals flying faster than a biotech merger rumor.

Chicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS ...

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to ...